Drs. Cosman and Bilezikian discuss the optimal use of denosumab in patients with postmenopausal osteoporosis and examine how RANK ligand inhibitors differ from bisphosphonate medications. They also share insight into how they personalize therapy with denosumab in patients with postmenopausal osteoporosis.
